:

Jieni Li1, George J Hutton2, Tyler J Varisco1,3

  • 1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas, USA.

概括

针对多发性硬化症 (MS) 的高疗效疾病修饰剂 (heDMA) 与中等疗效药物相比,增加了严重感染和尿路感染 (UTI) 的风险. 对于在heDMAs的患者来说,仔细监测至关重要.